Predicine, INC.

Predicine, INC. was paid $12.28M by Medicaid between Dec 2020 and Jun 2023, across 9 billing codes. Its largest line is U0003, Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r — 56% of everything it billed.

33Billing provider infoPREDICINE, INC.
HAYWARD, CA 94545

33aNPI1851992127assigned 11/03/2020

33bProvider typeClinical Medical Laboratory

28Total paid$12.28M

24GClaims373,344

24DCodes billed9

24AFirst – last monthDec 2020 – Jun 2023

Compared with peers

Next to other Clinical Medical Laboratory providers in California

Rank by total paid#60 of 561

Median peer was paid$222K

This provider vs. median55×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2020	511	$24K
2021	48,433	$1.79M
2022	230,914	$7.17M
2023	93,486	$3.30M

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
U0003	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r	56%	136,812	84,219	$6.90M
87811	Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19)	18%	75,806	29,133	$2.25M
G2023	Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source	12%	95,905	53,237	$1.42M
87636	Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B	8.4%	10,802	5,214	$1.03M
U0005	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	4.3%	50,382	33,736	$534K
87635	Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe	1.2%	3,363	2,505	$142K
87426	Infectious agent antigen detection, SARS-CoV-2 (COVID-19)	<1%	152	77	$5K
10005		<1%	21	20	$1K
99199	Unlisted special service, procedure or report	<1%	101	72	$42.37

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialWANG, QIAN (CFO)

Same official

Other billing entities under WANG, QIAN

Full network →

Provider	Location	Paid
TCM Acupuncture & Herb INC.	Moreno Valley, CA	$4K

Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.